Literature DB >> 7614777

Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children.

K T Olkkola1, K Hamunen, E L Maunuksela.   

Abstract

Pain in childhood has not always been managed as actively as that in adults because of the limited amount of research available to provide guidelines for the management of paediatric pain. However, for many years now the pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children have been studied intensively. Morphine is the standard for opioid analgesics and its pharmacology is the best studied in paediatric patients. During the neonatal period, the volume of distribution (Vd) appears to be smaller in neonates than in adults, but adult values are reached soon after the neonatal period. Although morphine is absorbed both orally and rectally, there is little information on the pharmacokinetics of morphine administered by these routes. The bioavailability of morphine after rectal administration appears to be highly variable. For all the opioid analgesics studied, the elimination of the opioids is slower in neonates than in adults. However, the rate of elimination usually reaches and even exceeds adult values within the first year of life. The high rate of drug metabolism means higher dosage requirements. In regard to the pharmacodynamics of opioid analgesics, infants and children do not appear to be more sensitive to the effects of opioids than adults. Thus, except for the neonatal period, the pharmacokinetics and pharmacodynamics of opioid analgesics are not markedly different from those of adults, and the risk of using opioids in infants and children is not higher.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7614777     DOI: 10.2165/00003088-199528050-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  137 in total

1.  Influence of gestational age on pharmacokinetics of alfentanil in neonates.

Authors:  A Killian; P J Davis; R L Stiller; R Cicco; D R Cook; R D Guthrie
Journal:  Dev Pharmacol Ther       Date:  1990

2.  Pharmacokinetics of sufentanil in adolescent patients with chronic renal failure.

Authors:  P J Davis; R L Stiller; D R Cook; B W Brandom; K A Davin-Robinson
Journal:  Anesth Analg       Date:  1988-03       Impact factor: 5.108

3.  Disposition of meperidine and normeperidine following multiple doses during labor. II. Fetus and neonate.

Authors:  B R Kuhnert; P M Kuhnert; E H Philipson; C D Syracuse
Journal:  Am J Obstet Gynecol       Date:  1985-02-01       Impact factor: 8.661

4.  The maturation of morphine clearance and metabolism.

Authors:  T I McRorie; A M Lynn; M K Nespeca; K E Opheim; J T Slattery
Journal:  Am J Dis Child       Date:  1992-08

5.  Effects of age on plasma protein binding of sufentanil.

Authors:  C Meistelman; D Benhamou; J Barre; J C Levron; V Mahe; X Mazoit; C Ecoffey
Journal:  Anesthesiology       Date:  1990-03       Impact factor: 7.892

6.  Combination therapy with ibuprofen and methadone for chronic cancer pain.

Authors:  T Ferrer-Brechner; P Ganz
Journal:  Am J Med       Date:  1984-07-13       Impact factor: 4.965

7.  Meperidine and normeperidine levels following meperidine administration during labor. II. Fetus and neonate.

Authors:  B R Kuhnert; P M Kuhnert; A S Tu; D C Lin
Journal:  Am J Obstet Gynecol       Date:  1979-04-15       Impact factor: 8.661

8.  Postoperative pain control with methadone: influence of supplementary methadone doses and blood concentration--response relationships.

Authors:  G K Gourlay; R J Willis; P R Wilson
Journal:  Anesthesiology       Date:  1984-07       Impact factor: 7.892

Review 9.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

10.  Alfentanil in infants and children with congenital heart defects.

Authors:  J M den Hollander; P J Hennis; A G Burm; J G Bovill
Journal:  J Cardiothorac Anesth       Date:  1988-02
View more
  17 in total

1.  Can we use methadone for analgesia in neonates?

Authors:  S K Chana; K J Anand
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-09       Impact factor: 5.747

2.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

Review 3.  [Buprenorphine in children. A clinical and pharmacological review].

Authors:  E Michel; B Zernikow
Journal:  Schmerz       Date:  2006-02       Impact factor: 1.107

4.  Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

Review 5.  Ketorolac for postoperative pain management in children.

Authors:  J B Forrest; E L Heitlinger; S Revell
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.606

Review 6.  Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.

Authors:  J Scholz; M Steinfath; M Schulz
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 7.  Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

8.  Protein binding predictions in infants.

Authors:  Patrick J McNamara; Jane Alcorn
Journal:  AAPS PharmSci       Date:  2002

Review 9.  Clinical pharmacology of analgosedatives in neonates: ways to improve their safe and effective use.

Authors:  Anne Smits; John N van den Anker; Karel Allegaert
Journal:  J Pharm Pharmacol       Date:  2016-06-30       Impact factor: 3.765

Review 10.  Pain treatment in multimorbid patients, the older population and other high-risk groups. The clinical challenge of reducing toxicity.

Authors:  C H Wilder-Smith
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.